AI English summary of an SEC filing — figures as filed
DuPont DDDuPont entered into a Transaction Agreement with Arclin on August 29, 2025 to sell its Aramids business (Kevlar and Nomex) in a transaction valuing the business at approximately $1.8 billion, subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals.
Key points
AI summaryDuPont entered into a Transaction Agreement with Arclin on August 29, 2025 to sell its Aramids business (Kevlar and Nomex) in a transaction valuing the business at approximately $1.8 billion, subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals.
The company said that at closing it will receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in Arclin currently valued at $325 million.
DuPont said the transaction is expected to close in Q1 2026, and that its equity interest in Arclin is expected to represent an approximate 17.5% stake at the time of closing, subject to customary closing conditions and regulatory approval.
The company said the Aramids business has approximately 1,900 employees and 5 manufacturing sites and generated net sales of $1.3 billion in 2024, and added that the divestiture will not impact DuPont's intended separation of its electronics business (Qnity), which remains on track for a November 1, 2025 spin-off.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
DuPont Enters into Agreement to Divest Aramids Business to Arclin
DuPont entered into a Transaction Agreement with Arclin on August 29, 2025 to sell its Aramids business (Kevlar and Nomex) in a transaction valuing the business at approximately $1.8 billion, subject to the satisfaction of customary closing conditions, including the receipt of regulatory approvals.
Source · Based on the filing body and exhibits
Consideration at Closing
The company said that at closing it will receive pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in Arclin currently valued at $325 million.
Source · Based on the filing body and exhibits
Closing timing and retained stake
DuPont said the transaction is expected to close in Q1 2026, and that its equity interest in Arclin is expected to represent an approximate 17.5% stake at the time of closing, subject to customary closing conditions and regulatory approval.
Source · Based on the filing body and exhibits
Aramids Business Scale and Qnity Separation Timeline
The company said the Aramids business has approximately 1,900 employees and 5 manufacturing sites and generated net sales of $1.3 billion in 2024, and added that the divestiture will not impact DuPont's intended separation of its electronics business (Qnity), which remains on track for a November 1, 2025 spin-off.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…